Literature DB >> 19127570

Treatment of intestinal and hepatic mucormycosis in an immunocompromized child.

Sonja Lüer1, Steffen Berger, Miriam Diepold, Andrea Duppenthaler, Michael von Gunten, Konrad Mühlethaler, Rainer Wolf, Christoph Aebi.   

Abstract

During ALL chemotherapy, a 4-year-old patient presented with febrile neutropenia and abdominal pain. Ultrasound examinations were repeatedly normal. Computerized tomography on day 7 demonstrated appendicitis and multiple hepatic foci identified as mucormycosis (Absidia corymbifera). Successful outcome was achieved by aggressive re-surgery, long-term antifungal therapy with serum level-monitored posaconazole, and recovery of neutrophil counts. Considering the interference of posaconazole with CYP3A4, vincristine was administered during 72 hr posaconazole windows. Pediatric intestinal mucormycosis, still associated with a >70% case-fatality rate, calls for early imaging and surgery to establish the diagnosis, reduce the fungal mass, and provide a rationale for using posaconazole. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19127570     DOI: 10.1002/pbc.21918

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  1 in total

1.  Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review.

Authors:  T Jancel; P A Shaw; C W Hallahan; T Kim; A F Freeman; S M Holland; S R Penzak
Journal:  J Clin Pharm Ther       Date:  2016-12-16       Impact factor: 2.512

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.